Agilent Technologies, Inc. · NYSE:A
Agilent Technologies — Q4 2020 Earnings Presentation
8 slides from Agilent Technologies's earnings presentation, November 2020
Slide 1: Agilent Technologies Q4'20 Results Presentation
Agilent Technologies Q4'20 Results Presentation
Slide 2: Safe Harbor
Safe Harbor This presentation contains forward-looking statements (including, without limitation, information, and future guidance on the company’s goals, priorities, revenue, revenue growth, earnings per share, operating margin, operating cash flow, capital expenditures, capital allocation, growth
Slide 3: Agilent Results Q4'20
Agilent Results Q4'20 Scale and leading technology across Analytical Laboratories and Clinical & Dx markets Q4'20 Financial Metrics FY20 Highlights • Revenues: $1.48B, +5.6% y/y • Revenue: Core revenue growth of 0.9%. Mid-single-digit core(1)(2),+8.5% reported (+1.2% M&A, growth in services and cons
Slide 4: Life Sciences & Applied Markets Group (LSAG)
Life Sciences & Applied Markets Group (LSAG) • Q4 Core Revenue performance reflected generally Instrumentation and Informatics improving conditions across geographies led by for Analytical Laboratories growth in the Food, Pharma, and C&E markets, and highlighted by strength in Cell Analysis and Mass
Slide 5: Agilent Cross Lab Group (ACG)
Agilent Cross Lab Group (ACG) • Strong revenue performance in Q4 reflected the Analytical Laboratory Consumables and Services continued resiliency of the business during the pandemic and the generally improving lab operating environments. Growth was broad across major markets and regions. • ACG grew
Slide 6: Diagnostics and Genomics Group (DGG)
Diagnostics and Genomics Group (DGG) • Q4 core revenue growth driven by strong Pharma Pathology, Genomics, and market, including continued strong ramp in NASD. Nucleic Acid Manufacturing • Announced the expansion of Visiopharm’s validated image analysis algorithm to incorporate HercepTest™ mAb pharm
Slide 7: Growth in a $58B Market – Q4'20 Results by End Market
Growth in a $58B Market – Q4'20 Results by End Market Strong Gains in Pharma & Food; Return to Growth in Chem & Energy Analytical Laboratory End Markets ▪ Q4'20 revenues: +6% y/y on core(2) basis ▪ Pharma & Biotech: Up 12% with strength across geographies, Chemical led by +DD growth in large molecul
Slide 8: Q1'21 and FY21 Guidance and Forward-looking Considerations
Q1’21 and FY21 Guidance and Forward-looking Considerations Based on October 31, 2020 Exchange Rates Q1’21 Guidance (1) FY21 Guidance (1) Low End High End Low End High End Net Revenue ($M) $1,420 $1,430 Net Revenue ($M) $5,600 $5,700 Y/Y Core Revenue Growth (2) 3.5% 4.5% Y/Y Core Revenue Growth (2) 4